Texan Capital Management maintained its stake in Pfizer Inc. (NYSE:PFE) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,325 shares of the biopharmaceutical company’s stock at the end of the second quarter. Texan Capital Management’s holdings in Pfizer were worth $434,000 at the end of the most recent reporting period.
A number of other hedge funds also recently added to or reduced their stakes in the company. Ronna Sue Cohen boosted its stake in Pfizer by 0.4% in the second quarter. Ronna Sue Cohen now owns 7,881 shares of the biopharmaceutical company’s stock worth $277,000 after buying an additional 35 shares during the period. Forte Capital LLC ADV boosted its stake in Pfizer by 0.4% in the first quarter. Forte Capital LLC ADV now owns 8,589 shares of the biopharmaceutical company’s stock worth $255,000 after buying an additional 36 shares during the period. Naples Global Advisors LLC boosted its stake in Pfizer by 0.4% in the second quarter. Naples Global Advisors LLC now owns 24,327 shares of the biopharmaceutical company’s stock worth $857,000 after buying an additional 85 shares during the period. Lincoln Capital LLC boosted its stake in Pfizer by 1.1% in the second quarter. Lincoln Capital LLC now owns 8,443 shares of the biopharmaceutical company’s stock worth $297,000 after buying an additional 94 shares during the period. Finally, Donald L. Hagan LLC boosted its stake in Pfizer by 0.9% in the second quarter. Donald L. Hagan LLC now owns 11,006 shares of the biopharmaceutical company’s stock worth $388,000 after buying an additional 97 shares during the period. Institutional investors own 69.65% of the company’s stock.
Pfizer Inc. (NYSE:PFE) traded up 0.56% during mid-day trading on Tuesday, hitting $33.83. 15,491,512 shares of the company were exchanged. The stock has a market cap of $205.20 billion, a price-to-earnings ratio of 29.99 and a beta of 0.87. Pfizer Inc. has a 12 month low of $28.25 and a 12 month high of $37.39. The firm has a 50 day moving average price of $34.63 and a 200 day moving average price of $34.00.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.02. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The business earned $13.10 billion during the quarter, compared to the consensus estimate of $13.01 billion. During the same period in the previous year, the business earned $0.56 EPS. The business’s quarterly revenue was up 10.9% on a year-over-year basis. Analysts anticipate that Pfizer Inc. will post $2.46 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be given a dividend of $0.30 per share. The ex-dividend date is Tuesday, November 8th. This represents a $1.20 dividend on an annualized basis and a yield of 3.55%. Pfizer’s dividend payout ratio is currently 95.24%.
A number of research firms have issued reports on PFE. Argus reissued a “buy” rating and set a $39.00 price target on shares of Pfizer in a research report on Sunday, August 28th. Sanford C. Bernstein reissued an “outperform” rating on shares of Pfizer in a research report on Monday. Jefferies Group reissued a “buy” rating and set a $42.00 price target (up from $41.00) on shares of Pfizer in a research report on Tuesday, June 14th. Vetr lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating and set a $37.28 price target for the company. in a research report on Tuesday, June 28th. Finally, Citigroup Inc. reissued a “neutral” rating and set a $37.00 price target on shares of Pfizer in a research report on Wednesday, August 3rd. Ten research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $38.78.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.